Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events

Kerkelä, Risto; Ulvila, Johanna; Magga, Johanna

doi:10.1161/jaha.115.002423

Cited by 131 publications

(132 citation statements)

References 134 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…59 Both atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) predominantly act on natriuretic peptide receptor A, which leads to the inhibition of the renin-angiotensinaldosterone system, diuresis, and natriuresis. 59 Secretion of ANP and BNP is both increased during hemodynamic overload and cardiac remodeling and are therefore indicative of heart failure ( Table 3). 59 Additional markers of hemodynamic stress and renal disturbance include copeptin and cystatin-C, respectively (Table 3).…”

Section: Risk Markers Related To Hemodynamic Stress and Renal Functionmentioning

confidence: 99%

See 1 more Smart Citation

Novel Risk Markers and Risk Assessments for Cardiovascular Disease

Thomas

Lip

2017

Circulation Research

117

View full text Add to dashboard Cite

Abstract:The use of risk markers has transformed cardiovascular medicine, exemplified by the routine assessment of troponin, for both diagnosis and assessment of prognosis in patients with chest pain. Clinical risk factors form the basis for risk assessment of cardiovascular disease and the addition of biochemical, cellular, and imaging parameters offers further refinement. Identifying novel risk factors may allow greater risk stratification and a steady, but gradual progression toward precision medicine. Indeed, the generation of data in this area of research is explosive and when combined with new technologies and techniques provides the potential for more refined, targeted approaches to cardiovascular medicine. Although discussing the most recent developments in this field, this review article aims to strike a balance between novelty and validity by focusing on recent large samplesize studies that have been validated in a separate cohort in most cases. Risk markers related to atherosclerosis, thrombosis, inflammation, cardiac injury, and fibrosis are introduced in the context of their pathophysiology. Rapidly developing new areas, such as assessment of micro-RNA, are also explored. Subsequently the prognostic ability of these risk markers in coronary artery disease, heart failure, and atrial fibrillation is discussed in detail. ( addition to these roles in the pathogenesis of coronary artery disease, lipid-related molecules have been identified to be markers of inflammation and oxidative stress (Table 1). Thrombosis-Related Risk MarkersAfter atherosclerotic plaque rupture, platelets adhere to exposed subendothelial components, such as collagen and von Willebrand factor, which promotes platelet activation and aggregation. 10 In addition, platelet activation is potentiated by exposure to released soluble agonists, such as thrombin and ADP.10 Activated platelets then further release ADP, which acts on platelet P2Y 12 ADP receptors and has a central role in amplifying the response of platelets to the initial stimulus. 10 Platelet reactivity to various agonists, including ADP, has been studied extensively in the context of acute coronary syndrome (ACS; Table 2). 11 The VerifyNow and Multiplate pointof-care tests allow for the measurement of platelet aggregation in response to stimulation, and it has been shown that high platelet reactivity is associated with adverse cardiovascular events. 26 Platelet microparticles are released on platelet activation, and their role in cardiovascular disease is an area of active investigation (Table 2). 15 Circulating microparticles are released from cells undergoing activation or apoptosis and are a type of small plasma membrane vesicle that retain defined properties from their original cell lineage. 15 Platelet activation and aggregation lead to the activation of the coagulation cascade and the formation of a stable crosslinked fibrin clot. The balance between prothrombotic factors and endogenous fibrinolysis determines whether the thrombus propagates or instead proceeds to dis...

show abstract

Section: Risk Markers Related To Hemodynamic Stress and Renal Functionmentioning

confidence: 99%

“…59 Secretion of ANP and BNP is both increased during hemodynamic overload and cardiac remodeling and are therefore indicative of heart failure (Table 3). 59 Additional markers of hemodynamic stress and renal disturbance include copeptin and cystatin-C, respectively (Table 3). …”

mentioning

confidence: 99%

Novel Risk Markers and Risk Assessments for Cardiovascular Disease

Thomas

Lip

2017

Circulation Research

117

View full text Add to dashboard Cite

show abstract

“…The latter consist of a family of peptides which have a wide range of cardiovascular effects including amelioration of volume overload and hypertension. 29 While the inhibitory effect of NPs on the RAAS pathway undoubtedly plays a major role in their cardioprotective characteristics, there is also evidence that NPs have important cardioprotective antioxidant, anti-inflammatory and antifibrotic properties. 29,30 For example, NPs have been shown to inhibit activation of the nuclear factor NF-ĸB and reduce the production of inflammatory mediators in macrophages, endothelial cells and cardiomyocytes.…”

Section: Discussionmentioning

confidence: 99%

LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease

Suematsu

Jing

Nunes

et al. 2018

Journal of Cardiac Failure

View full text Add to dashboard Cite

Highlights The effect of LCZ696 (Sacubitril/valsartan) against cardiorenal syndrome is proposed. LCZ696 more improved CKD related heart failure than valsartan therapy alone. LCZ696 attenuated CKD related cardiac hypertrophy and fibrosis and aortic fibrosis. Effects of LCZ696 for heart are mediated by anti-inflammation and oxidative stress. LCZ696 also improved indicators of mitochondrial mass/function. AbstractBackground: Chronic kidney disease (CKD) is associated with cardiac hypertrophy, fibrosis and

show abstract

“…Ключевую роль в их действии на сердечно-сосудистую систему и почки играет активация системы НУП, прежде все-го предсердного (ПНП) и мозгового (МНП) натрий-уретических пептидов, которые реализуют свои био-логические эффекты в кардиомиоцитах и других клет-ках-мишенях через возбуждение гуанилатциклазных рецепторов А-типа (ГЦР-А), вызывающих повышение активности трансмембранной гуанилатциклазы (ГЦ) и увеличение внутриклеточной концентрации цикли-ческого гуанозинмонофосфата (цГМФ) [12]. В обыч-ных условиях ПНП и, в меньшей степени, МНП син-тезируются и сохраняются в виде пропептидов в гра-нулах кардиомиоцитов предсердий, из которых ПНП в ответ на напряжение предсердной стенки секрети-руется как активный пептид, а МНП первоначально выделяется в виде проМНП, превращающегося затем в неактивный N-концевой проМНП (NT-proBNP) и активный МНП [13].…”

Section: Discussionunclassified

“…Биологические эффекты, скоординированно возникающие под влиянием НУП в сердце, почках и глад-кой мускулатуре сосудов, ослабляют повреждающее действие этих нейрогормональных систем, способствуя сохранению водно-солевого гомеостаза организма и под-держанию адекватного АД [12].…”

Section: Discussionunclassified

Clinical efficacy of dual inhibitor of neprilisin and AT1‑angiotensin receptors LCZ696 (sakubitril/valsartan) in chronic heart failure patients with impaired renal function

Кузьмин¹,

Zezha²,

Belyanin³

et al. 2017

RHFJ

View full text Add to dashboard Cite

Резюме В обзоре представлены сведения об участии натрийуретических пептидов в нейрогормональном механизме, препятствующем повреждению сердца и почек у больных ХСН, и результаты, полученные при оценке клинической эффективности LCZ696 (сакубитрил / валсартан) в этой популяции пациентов, включая лиц с нарушенной функцией почек.Kuzmin O. B

show abstract

Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events

Cited by 131 publications

References 134 publications

Novel Risk Markers and Risk Assessments for Cardiovascular Disease

Novel Risk Markers and Risk Assessments for Cardiovascular Disease

LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease

Clinical efficacy of dual inhibitor of neprilisin and AT1‑angiotensin receptors LCZ696 (sakubitril/valsartan) in chronic heart failure patients with impaired renal function

Contact Info

Product

Resources

About